Skip to main content
BEIJING LEADMAN BIOCHEMISTRY CO.,LTD. logo

BEIJING LEADMAN BIOCHEMISTRY CO.,LTD. — Investor Relations & Filings

Ticker · 300289 ISIN · CNE100001C22 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,952 across all filing types
Latest filing 2025-11-13 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300289

About BEIJING LEADMAN BIOCHEMISTRY CO.,LTD.

https://www.leadmanbio.com

Beijing Leadman Biochemistry Co., Ltd. specializes in the research, development, manufacturing, and distribution of in-vitro diagnostic (IVD) solutions. The company’s core portfolio includes a wide range of clinical chemistry reagents, chemiluminescence immunoassay kits, and automated diagnostic instruments. These products support various medical testing areas, such as liver and kidney function, lipid profiles, and cardiac markers. By providing integrated systems that combine high-performance reagents with specialized hardware, the company serves hospitals, clinical laboratories, and medical institutions. Its operations focus on delivering precise and efficient diagnostic tools to enhance clinical decision-making and patient care.

Recent filings

Filing Released Lang Actions
中信建投证券股份有限公司关于本次交易摊薄上市公司即期回报情况及填补措施的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed independent financial advisor's verification opinion regarding the dilution impact of a transaction on the listed company's immediate returns and the measures to compensate for it. It includes financial data comparisons before and after the transaction, commitments from the company's directors and controlling shareholders, and an overall opinion on the transaction's impact on earnings per share. The document is not a full annual or interim report but a specialized verification opinion related to a capital market transaction and its impact on shareholder returns. This fits the category of Capital/Financing Update (CAP), as it concerns a transaction affecting the company's capital structure and earnings per share, with detailed financial analysis and commitments. The document length is 3351 characters, which is substantive and contains financial data and analysis, not just an announcement or certification. Therefore, the best classification is CAP with high confidence.
2025-11-13 Chinese
中信建投证券关于本次交易符合《创业板上市公司持续监管办法（试行）》第十八条和《深圳证券交易所上市公司重大资产重组审核规则》第八条规定的核查意见
M&A Activity Classification · 95% confidence The document is a formal opinion from an independent financial advisor (中信建投证券股份有限公司) regarding the compliance of a proposed transaction with specific regulatory rules related to major asset restructuring for a company listed on the Shenzhen Stock Exchange's Growth Enterprise Market (创业板). It discusses the transaction details, industry classification, and regulatory compliance under the '创业板上市公司持续监管办法（试行）' and '深圳证券交易所上市公司重大资产重组审核规则'. The document is not a full financial report but a compliance and advisory opinion related to a major asset restructuring transaction. This fits the category of M&A Activity (TAR), which covers announcements and documents related to merger proposals or takeover bids, including major asset restructuring compliance opinions. The document length is short (1260 characters), but it contains substantive content about the transaction and regulatory compliance, not just an announcement of a report publication or a certification. Therefore, the best classification is TAR with high confidence.
2025-11-13 Chinese
关于标的资产权属情况及合法合规经营情况的承诺
M&A Activity Classification · 95% confidence The document consists primarily of multiple formal commitment and warranty statements related to a major asset acquisition transaction involving Beijing Lidemann Biochemical Co., Ltd. and the purchase of 70% equity in Beijing Xiansheng Xiangrui Biological Products Co., Ltd. The text includes detailed legal assurances about the ownership, legality, compliance, and absence of insider trading or disqualifications related to the transaction. There are no financial statements, earnings data, or management discussion of financial results. The document is not a full annual or interim report, nor is it a call transcript or presentation. It is a set of legal and compliance commitments related to a merger or acquisition transaction. Therefore, the document best fits the category of M&A Activity (TAR), which covers announcements and documents related to merger proposals or takeover bids. The document length is substantial and contains the actual commitments, not just an announcement of a report, so it is not a Report Publication Announcement or Regulatory Filing. Hence, the classification is TAR with high confidence.
2025-11-13 Chinese
中信建投证券股份有限公司关于本次交易符合上市公司监管指引第9号——上市公司筹划和实施重大资产重组的监管要求第四条规定的核查意见
Audit Report / Information Classification · 95% confidence The document is a verification opinion from an independent financial advisor (中信建投证券股份有限公司) regarding a transaction involving a major asset restructuring by a listed company (北京利德曼生化股份有限公司). It references compliance with regulatory guidelines for major asset restructurings (上市公司监管指引第9号). The document provides an opinion on the transaction's compliance but does not contain financial statements or detailed financial data. It is a standalone audit or verification report related to a specific transaction, not a full annual or interim report. The document length is short (1046 characters), and it is not an announcement of a report publication but the report itself. Therefore, it fits best under Audit Report / Information (AR).
2025-11-13 Chinese
中信建投证券股份有限公司关于本次交易符合上市公司重大资产重组管理办法第十一条及不适用第四十三条、第四十四条规定的核查意见
Regulatory Filings Classification · 95% confidence The document is a verification opinion from an independent financial advisor (中信建投证券股份有限公司) regarding a major asset restructuring transaction by a listed company. It references compliance with specific regulatory provisions (《上市公司重大资产重组管理办法》第十一条及不适用第四十三条、第四十四条) and confirms the transaction's fairness and legality. The document is relatively short (1103 characters) and serves as a formal opinion or certification rather than a full report containing financial statements or detailed analysis. It does not present comprehensive financial data or management discussion but rather a compliance check and opinion on the transaction. Therefore, it is best classified as a Regulatory Filing (RNS), which covers miscellaneous regulatory announcements and compliance documents that do not fit other categories.
2025-11-13 Chinese
中信建投证券股份有限公司关于上市公司内幕信息知情人登记制度的制定和执行情况之专项核查意见
Regulatory Filings Classification · 95% confidence The document is a special inspection opinion by an independent financial advisor (中信建投证券股份有限公司) regarding the establishment and execution of the insider information registration system of a listed company in relation to a specific transaction. It discusses compliance with laws and confidentiality measures but does not contain financial statements or detailed financial data. It is not an annual or interim report, earnings release, or any direct financial disclosure. It is a regulatory compliance and procedural report related to insider information management and confidentiality in a transaction. The document length is short (1339 characters), and it is a standalone opinion report, not an announcement of a report publication. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory compliance documents that do not fit other specific categories.
2025-11-13 Chinese

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.